Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENG-E2 vaginal ring metabolic profile versus LNG-EE oral contraceptive and no treatment
NL-OMON43381Phase 1Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Apr 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of etonogestrel and estradiol in contraception (3 arms), sponsored by Merck & Co. Primary endpoint: Change from baseline to end of Cycle 3 in key hemostatic parameters. Started Apr 2016; status: active, not recruiting.
02
Drugs
etonogestrelestradiol
03
Conditions
contraception
Beyond the preview
Go deeper on NL-OMON43381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43381.